摘要
目的评价雷替曲塞联合奥沙利铂（L-0HP）治疗晚期肠癌的疗效和安全性。方法经病理组织学或细胞学明确诊断的晚期肠癌患者30例，随机分为雷替曲塞联合奥沙利铂治疗（观察组）和FOLFOX改进方案治疗（对照组）两组，每组15例。观察组予雷替曲塞3mg/m2，第1天，静脉注射30min，奥沙利铂130mg/m2，第1天，静脉滴注3h，每3周重复1次。对照组用FOLFOX改进方案，奥沙利铂130mg/m2，第1天，静脉滴注3h，亚叶酸钙200mg/m2，静脉滴注2h，5-Fu 400mg/m2静脉推注，第1天，然后3000mg/m2持续46h微泵静脉推注，每3周重复1次。结果两组各有14例可评价，有效率分别为35.7％和21.4％，中位疾病进展时间（TTP）分别为8.2个月和4.9个月，两组疗效比较差异有统计学意义（P〈0.05）。结论老年晚期结直肠癌的治疗雷替曲塞联合奥沙利铂方案优于FOLFOX方案。
Objective To assess the effect and security of Raltitrexed plus Oxaliplatin in treatment of advanced colorectal cancer. Methods 30 cases of advanced colorectal cancer were divided into two groups,15 cases in treatment group were given intravenously raltitrexed 15 min drip with 3mg/m2 on day 1,oxaliplatinl 3-hour drip with 130mg/m2 on day 1.The regimen was repeated every 3 weeks was a cycle. 15cases in matched groupwere given oxaliplatinl 130mg/m2 over 3 hours infusion on day 1, Leucovorin Calcium 200mg/m2 infusion over 2 hours on day 1 and 5-fluorouracil 400mg/m2 IV on day 1,5-fluorouracil 3000mg/m2 IV maintenance 46hours . The regimen was repeated every 3 weeks was a cycle. The data was evaluated from the 2 groups.Resluts 14 cases of every group were evaluated,RR were 35.7% and 21.4%,TTP were 8.2 and 4.9 mouths,respectively（P〈0.05）. Conclusion The clinical efficacy of raltitrexed plus oxaliplatinl is better than 5-fluorouracil and leucovorin plus oxaliplatint.
出处
《浙江临床医学》
2013年第8期1112-1114,共3页
Zhejiang Clinical Medical Journal
基金
国家自然科学基金课题：肠癌干细胞来源的伴侣分子疫苗抗原肽谱及其免疫学特性研究（编号：81072495）
关键词
晚期肠癌
雷替曲塞
奥沙利铂
Colorectal cancer Raltitrexed Oxaliplatinl
